← FDA DRUG APPROVALS

FDA ANDA · ANDA208427

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

Sponsor: DR REDDYS

APPLICATION
ANDA208427
TYPE
ANDA
ORIGINAL APPROVAL
2025-11-03
LATEST ACTION
2025-11-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LINAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 1GM · TABLET · ORAL
LINAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
LINAGLIPTIN AND METFORMIN HYDROCHLORIDEPrescription
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 850MG · TABLET · ORAL

Approval history

2025-11-03UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →